Nanomedicine News

RSS

Cascade Nano-Bioreactor Designed for Synergistic Tumor Therapy

A new study demonstrates a nano-based cancer-targeted cascade bioreactor developed by inserting catalase (CAT), chlorin e6 (Ce6), and glucose oxidase (GOx) into human serum albumin (HSA) self-assembly molecules, for synergistic starvation and photodynamic therapy (PDT).

28 Sep 2022

Biodegradable, Long-Acting Androgenic Alopecia Treatment System

An article published in the journal Drug Delivery presented a nanostructured lipid carrier (lipid nanoparticle)-based transdermal drug delivery system of BS and integrated it into polymeric microneedle (MN).

27 Sep 2022

Single Dose Nanovaccine Developed to Help Tackle Shigella

An article published in Molecular Pharmaceutics presented an extension of a previous work that demonstrated the stabilization of “invasion plasmid antigen C” (IpaC) protein by using Shigella dysenteriae serotype 1 (Sd1)-based recombinant to induce immune responses in BALB/c mice.

23 Sep 2022

Nanoengineers Develop Pneumonia-Fighting Microrobots

UC San Diego engineers have developed microscopic robots, called microrobots, that can swim around in the lungs, deliver medication and be used to clear up life-threatening cases of bacterial pneumonia. In mice, the microrobots safely eliminated pneumonia-causing bacteria in the lungs and resulted in 100% survival.

23 Sep 2022

Novel Nanocarriers to Transport Drug Payloads to the Brain

Researchers have formulated a new method for creating drug-delivering nanocarriers, comprising of a soft, fat-like, liposome interior enclosed by a firm shell of gold nanoparticles.

21 Sep 2022

Spago Nanomedical Gets SpagoPix Abstract Accepted at Breast Cancer Conference

Spago Nanomedical AB (publ) today announced that an abstract, concluding the initial results from the First-In-Human Phase I clinical trial SPAGOPIX-01, has been accepted for poster presentation at the 2022 San Antonio Breast Cancer Symposium® (SABCS) on December 6-10, 2022.

From Spago Nanomedical AB 21 Sep 2022